Supporting Ultragenyx rare and ultra-rare metabolic and neuromuscular disease franchise, including Gene Therapy for GSDIa, OTC, WD, MPS IIIA, and CDDEnzyme Replacement Therapy for MPS VII, AS, CTD, and CDD.Supplementation for FAOD.

Ensure the appropriate dissemination of clinical and scientific information regarding marketed and pipeline compounds in a timely, ethical and customer-focused manner.Implement clinical and educational strategies in collaboration with other Novartis colleagues for designated customers that include potential clinical trial site placement and sponsorships.Work to pair key customers' educational and research needs with available Novartis resources and provide the latest emerging data in response to specific healthcare professional inquiries.

Scientific Liaison and Strategic Planning: Support advocacy development, insight generation, executive engagement, and speaker bureau operations. This includes planning/implementing peer-to-peer, online, and podium-based advocacy initiatives.KOL Management: Connect key opinion leaders (KOLs) with the appropriate training, medical, or senior leadership resources, preparing KOLs to advocate on behalf of the organization at scientific meetings. Relationship Building and KOL Identification: Identify, engage, and build relationships with 30–35 key KOLs in the medical field, ensuring availability of cross-functional commercial resources. Stakeholder Engagement: Collaborate with MSLs, regional directors, and area managers to effectively plan and carry out tactical initiatives. Scientific Communications: Communicate insights from the field to internal stakeholders, allowing organization to gauge KOL placement in the advocacy matrix and formulate strategic plans for advancement. Legal Compliance and Regulatory Compliance: Liaise with Medical Affairs, Marketing, Sales, and Market Access Departments, maintaining compliance with commercial regulations, approved standard operating procedures (SOPs), and legal/regulatory guidelines.

Subject Matter Experts and Therapeutic Areas: Led, coordinated, and planned commercial engagement with 30–35 thought leaders and emerging experts. Built and maintained effective relationships with experts in specialty therapeutic areas.Patient Outcomes: Promoted a better understanding of mechanisms of disease and appropriate solutions to improve patient outcomes.Biosimilars and Orphan Drugs: Supported the rare disease and orphan drug franchise (with a special focus on biosimilars), serving as advocacy and insight team lead.Medical Education and Peer-to-peer: Coordinated with Marketing Relations Department to identify and develop speaker candidates for promotional peer-to-peer medical education programs, facilitating 5–7 personal connections per month.Strategic Planning: Developed KOL engagement plans, resulting in improved territory resource application and service adoption.Training & Development: Provided support for speaker training and development related to disease state education.

Thought Leadership and Relationship Building: Identified, cultivated, and maintained long-standing relationships with national and regional experts/advisors.Data Analytics: Provided advocacy development for KOLs, gathered insights, and synthesized data and analysis. Legal Compliance: Collaborated across functions to ensure consistency with commercial compliance, regulatory, and legal guidelines.Cross-functional Collaboration: Served as speaker liaison, collaborating with marketing leadership and contracted speakers to support the evolution of programming content.

Thrombosis, Diabetes, Osteoarthritis, and Rheumatology: Built rapport and peer-to-peer relationships with medical and scientific leaders—including researchers, KOLs, and healthcare providers in thrombosis/cardiology, diabetes, and osteoarthritis/rheumatology.Pharmaceutical Research and Protocol Development: Supported development of investigator-initiated scientific protocols, driving product research and the development of academic literature based on findings.Field Work: Provided field-based medical and scientific information, responding to unsolicited requests for medication information regarding products and related therapeutic areas.Medical Affairs: Coordinated with academic, hospital, and specialty scientific communities, delivering medical affairs support for multiple products, including eptifibatide, sitagliptin, odanacatib, and vorapaxar. Clinical Strategy: Collected intelligence through scientific and medical exchange with clinical investigators and medical experts, providing key information to guide clinical strategies and drive medical insights.Networking: Sourced networking opportunities, connecting and engaging customer-facing team members. Clinical Trials and Cardiology: Facilitated clinical trial execution within the cardiology space, coordinating with institutions such as MedStar Health, University of Virginia, the Veterans Administration, and Virginia Commonwealth University.Scientific Communications: Served as primary resource for scientific congress, discussion with advisory boards, and training of colleagues, inviting a number of scientific leaders for discussion.